Back to mobile site

Oppenheimer Reiterates Outperform Rating on Regeneron Pharma (REGN)

May 30, 2025 8:39 AM EDT Send to a Friend
Oppenheimer analyst Hartaj Singh reiterated an Outperform rating and $900.00 price target on Regeneron Pharma (NASDAQ: REGN).The analyst comments "Regeneron ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login